NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- Emergency geohazard screening underway in quake-hit Xizang
- Top academics discuss how AI is reshaping communication and media
- Rainforest rendezvous shared with the world
- Global Education Deans' Forum eyes innovation-driven future
- SJTU hosts 1st Global PhD Student Forum for Interdisciplinary and Innovative Research
- China to send giant panda to Belgium, continuing conservation collaboration
